STE vs DXCM
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
STE · Steris PLC$255.76 ▲ 0.39%
DXCM · DexCom$79.32 ▼ 1.08%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- STE -0.5%
- DXCM +32.6%
Head to head
| Metric | STE | DXCM |
|---|---|---|
| Price | $255.76 | $79.32 |
| Change today | ▲ 0.39% | ▼ 1.08% |
| Market cap | $24.84B | $29.58B |
| Return, 3 months | +8.8% | -12.9% |
| Return, year to date | +1.8% | +19.5% |
| Return, 1 year | +1.3% | +31.7% |
| P/E (TTM) | 30.4 | 31.2 |
| P/B | 3.4 | 11.7 |
| P/E percentile vs own 5y | 21st | 6th |
| Dividend yield | 1.01% | – |
| Revenue growth (YoY, latest qtr) | +8.8% | +11.2% |
| Net profit growth (YoY) | +11.2% | -3.1% |
| Gross margin | 44.6% | 63.4% |
| Operating margin | 19.3% | 24.0% |
| Net margin | 13.4% | 19.4% |
| Return on equity | 11.6% | 37.7% |
| Analyst target vs. price | +12.8% | +25.1% |
| Analyst buy share | 100% | 93% |
| RSI (14) | 68 | 43 |
| 30-day volatility | 33.4% | 45.7% |
| Max drawdown, 1 year | -25.4% | -22.6% |
| Trend read | Strong uptrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- DXCM is the largest of the group by market value.
- DXCM has returned the most over the past year.
- STE carries the lowest trailing P/E.
- DXCM is growing revenue fastest.
- DXCM keeps the most profit per dollar of sales.
- STE has been the calmest stock over the last 30 days.